Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.064 AUD | +4.92% | +6.67% | -9.86% |
Apr. 04 | Noxopharm Receives AU$100,000 to Progress Brain Cancer Drug | MT |
Feb. 27 | Noxopharm Narrows Fiscal H1 Net Loss Despite Lower R&D Tax Incentive | MT |
Business Summary
Managers
Managers | Title | Age | Since |
---|---|---|---|
Gisela Mautner
CEO | Chief Executive Officer | - | - |
Director of Finance/CFO | - | 19-02-28 | |
Olivier Laczka
CTO | Chief Tech/Sci/R&D Officer | - | 19-10-15 |
Jeanette Bell
COO | Chief Operating Officer | - | 19-04-22 |
John Wilkinson
CTO | Chief Tech/Sci/R&D Officer | - | 18-01-31 |
Gregory Ambra
PRN | Corporate Officer/Principal | - | 19-10-15 |
Ron Sinani
LAW | General Counsel | - | 16-12-31 |
Alexander Hunter
PRN | Corporate Officer/Principal | - | 19-11-05 |
David Franks
SEC | Corporate Secretary | 53 | 17-01-15 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Fred Bart
CHM | Chairman | 69 | 20-05-07 |
Peter Marks
BRD | Director/Board Member | 68 | 16-03-14 |
Boris Patkin
BRD | Director/Board Member | - | 20-03-25 |
Gisela Mautner
CEO | Chief Executive Officer | - | - |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 292,237,950 | 189,349,920 ( 64.79 %) | 0 | 64.79 % |
Company contact information
Sector
1st Jan change | Capi. | |
---|---|---|
-9.86% | 12.2M | |
-4.66% | 86.13B | |
+1.32% | 39.82B | |
-19.27% | 30.42B | |
+57.86% | 25.23B | |
-17.69% | 11.6B | |
-43.00% | 11.51B | |
-9.14% | 11.95B | |
+5.24% | 8.71B | |
-8.42% | 8.12B |
- Stock Market
- Equities
- NOX Stock
- Company Noxopharm Limited